KRAS and neoplasm: However, Notta et al [9] have suggested that the switch in certain cases can be a result of simultaneous mutations in these genetic drivers and it has not been confirmed that KRAS is the gatekeeper required for neoplasia despite its occurrence in 70-90% of PDAC tissue.